| DC7180 |
KN-93 Phosphate
Featured
|
KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM). |
|
| DC8247 |
KNK437
Featured
|
KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40. |
|
| DC8788 |
Ko 143
Featured
|
Ko 143 is a potent and selective breast cancer resistance protein multidrug transporter (BCRP) inhibitor (EC90 = 26 nM), Ko 143 displays > 200-fold selectivity over P-gp and MRP-1 transporters. |
|
| DC10487 |
KO947
Featured
|
KO-947 is a small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2), as a potential treatment for cancers in which the mitogen activated protein kinase (MAPK) pathway. |
|
| DC7443 |
Kobe0065
Featured
|
Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM. |
|
| DC7444 |
kobe2602
Featured
|
kobe2602 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 149 ± 55 μM. |
|
| DC20097 |
Kojic acid
Featured
|
Kojic acid is a natural substance produced by Aspergillus oryzae, also used as an anti-oxidant and radio-protective agent. |
|
| DC9788 |
KP1019(FFC14A) |
KP1019 (FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials. |
|
| DC8575 |
KP372-1 |
KP372-1 is a specific Akt inhibitor that blocks proliferation and induces apoptosis of thyroid cancer cells with an IC50 value of 30-60 nM in vitro. |
|
| DC12108 |
KP-457
Featured
|
KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and 5050s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MM |
|
| DC7445 |
KPT-185 |
KPT-185 is an orally bioavailable selective inhibitor of CRM1 amd displayes potent antiproliferative properties at submicromolar concentrations,induced apoptosis (average 5-fold increase), cell-cycle arrest, and myeloid differentiation in AML cell lines a |
|
| DC7181 |
KPT-276
Featured
|
KPT-276, analog of KPT-185, is an orally bioavailable selective inhibitors of nuclear export (SINE) that irreversibly bind to CRM1 and block the function of CRM1. |
|
| DC7067 |
KPT-330(Selinexor)
Featured
|
KPT-330, analog of KPT-185, is an orally bioavailable selective CRM1 inhibitor. |
|
| DC11276 |
KPT-6566
Featured
|
KPT-6566 is a covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action. |
|
| DC26083 |
KR-32570 |
KR-32570 is a potent sodium hydrogen exchanger NHE1 inhibitor with IC50 of 50 nM. |
|
| DC23568 |
KR-33028 |
KR-33028 is a potent, highly selective NHE1 inhibitor with IC50 of 2.59 uM. |
|
| DC10041 |
KR-33494
Featured
|
KR-33494 is a fluorescent-tagged and biotin-tagged probe of a potent inhibitor for Fas-mediated cell death (FAF1), KR-33493. |
|
| DC12621 |
KR-62436 |
KR-62436 (KR62436) is a potent, selective DPP4 inhibitor with IC50 of 0.78, 0.49, 0.14 uM for rat plasma, porcine kidney, human DPP4 (Caco-2), respectively. |
|
| DC12652 |
KRAS G12C inhibitor 11 |
KRAS G12C inhibitor 11 is a potent, selective, covalent and irreversible inhibitor of KRAS G12C, inhibits KRAS dependent ERK-phosphorylation in the H358 cell with IC50 of 5 nM. |
|
| DC23806 |
KRAS inhibitor 11 |
KRAS inhibitor 11 is a first-in-class, high-affinity, noncovalent allosteric KRAS inhibitor, disrupts KRAS-Raf interaction with Kd of 1.2 uM. |
|
| DC11223 |
KRAS inhibitor C6ME |
KRAS inhibitor C6ME is a small-molecule compound that blocks biochemical and cellular functions of KRASG12V in vitro.. |
|
| DC11222 |
KRAS inhibitor Cmpd2 |
KRAS inhibitor Cmpd2 is a small-molecule compound that blocks biochemical and cellular functions of KRASG12V with IC50 of 0.8 uM in vitro. |
|
| DC7793 |
K RAS INHIBITOR-12
Featured
|
K-Ras(G12C) inhibitor 12 is an allosteric inhibitor of oncogenic K-Ras(G12C). |
-inhibitor-12-chemical-structure.gif)
|
| DC7446 |
K-Ras(G12C) inhibitor 6 |
K-Ras(G12C) inhibitor 6 is an allosteric, and selective inhibitor of oncogenic K-Ras(G12C). |
 inhibitor 6.gif)
|
| DC7722 |
K-RAS inhibitor 9
Featured
|
K-Ras(G12C) inhibitor 9 is an allosteric inhibitor of oncogenic K-Ras(G12C). |
|
| DC12704 |
KRAS4b-PDEδ stablizer C19 |
KRAS4b-PDEδ stablizer C19 is a small molecule that binds and stablizes the KRAS4b-PDEδ complex, decreases the viability and proliferation of colorectal cancer cells. |
|
| DC12588 |
KRAS-G12C inhibitor 13 |
KRAS-G12C inhibitor 13 is a potnt, irreversible, covalent and in vivo-active inhibitor of KRAS-G12C, suppresses ERK phosphorylation with IC50 of 70 nM in H358 cell assays. |
|
| DC9906 |
K-Ras-IN-1
Featured
|
K-Ras-IN-1 is a K-Ras inhibitor, by binding to K-Ras in a hydrophobic pocket that is occupied by Tyr-71 in the apo-Ras crystal structure. |
|
| DC8127 |
KRCA-0008
Featured
|
KRCA-0008 is a potent Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor (IC50 values are 4 and 12 nM respectively). |
|
| DC9963 |
Kribb11
Featured
|
KRIBB11 is a Heat shock factor (HSF) inhibitor (IC50 = 1.2 μM). |
|
